Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

SRx Health Solutions (SRXH) Accumulated Depreciation & Amortization (2016 - 2025)

SRx Health Solutions' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $31000.0 for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization fell 99.29% year-over-year to $31000.0; the TTM value through Sep 2025 reached $31000.0, down 99.29%, while the annual FY2025 figure was $31000.0, N/A changed from the prior year.
  • Accumulated Depreciation & Amortization reached $31000.0 in Q3 2025 per SRXH's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.6 million in Q2 2025 to a low of $31000.0 in Q3 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.0 million, with a median of $270000.0 recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 1524.81% in 2024, then crashed 99.29% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $206000.0 in 2021, then fell by 17.96% to $169000.0 in 2022, then skyrocketed by 892.9% to $1.7 million in 2023, then plummeted by 92.25% to $130000.0 in 2024, then plummeted by 76.15% to $31000.0 in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Accumulated Depreciation & Amortization are $31000.0 (Q3 2025), $4.6 million (Q2 2025), and $420000.0 (Q1 2025).